---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-214976"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:17:49.739425+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO

## Summary
- Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M of common stock in at-the-market offerings.
- Sandra Gardiner retiring as interim CFO effective May 15, 2026; Linda Rubinstein of FLG Partners will succeed her.
- Rubinstein has over 35 years experience, raised >$5B in financings, and previously CFO of Adverum Biotechnologies.
- Shares may be sold through ordinary brokers' transactions on Nasdaq at market prices; 3.0% commission fee to agents.

## SEC filing metadata
- accession: 0001193125-26-214976
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-214976
- JSON: https://secwatch.observer/filing/0001193125-26-214976.json
- Plain text: https://secwatch.observer/filing/0001193125-26-214976.txt

## Source-grounded claims
- claim_id: c637163245
  claim: Linda Rubinstein was appointed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.
  evidence_excerpt: Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm
- claim_id: eb697dfc1c
  claim: Sandra Gardiner departed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.
  evidence_excerpt: On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm
- claim_id: 601bef46dca020c84af9e47aeae1c7ade3ca6330
  claim: NEKTAR THERAPEUTICS entered into Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC valued at $150,000,000 (effective 2026-05-08).
  evidence_excerpt: On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.